Pharmacogenetics and drug-induced arrhythmias.

[1]  D M Roden,et al.  A common polymorphism associated with antibiotic-induced cardiac arrhythmia. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[2]  C. Antzelevitch,et al.  Effects of a K(+) channel opener to reduce transmural dispersion of repolarization and prevent torsade de pointes in LQT1, LQT2, and LQT3 models of the long-QT syndrome. , 2000, Circulation.

[3]  D. Roden.  Acquired Long QT Syndromes and the Risk of Proarrhythmia , 2000, Journal of cardiovascular electrophysiology.

[4]  C Antzelevitch,et al.  The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. , 2000, European heart journal.

[5]  E. Silverman,et al.  The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. , 2000, American journal of respiratory and critical care medicine.

[6]  A. Roses.  Pharmacogenetics and the practice of medicine , 2000, Nature.

[7]  S. Priori,et al.  Evidence for a Cardiac Ion Channel Mutation Underlying Drug‐Induced QT Prolongation and Life‐Threatening Arrhythmias , 2000, Journal of cardiovascular electrophysiology.

[8]  Jeffrey R. Balser,et al.  A sensitive mechanism for cation modulation of potassium current , 2000, Nature Neuroscience.

[9]  C. Wolf,et al.  Science, medicine, and the future: Pharmacogenetics. , 2000, BMJ.

[10]  R. Hetzer,et al.  β1-Adrenoceptor gene variations: a role in idiopathic dilated cardiomyopathy? , 2000, Journal of Molecular Medicine.

[11]  M. Relling,et al.  Pharmacogenomics: translating functional genomics into rational therapeutics. , 1999, Science.

[12]  D. Roden,et al.  Exaggerated QT prolongation after cardioversion of atrial fibrillation. , 1999, Journal of the American College of Cardiology.

[13]  M. Keating,et al.  MiRP1 Forms IKr Potassium Channels with HERG and Is Associated with Cardiac Arrhythmia , 1999, Cell.

[14]  B. Drolet,et al.  Thioridazine lengthens repolarization of cardiac ventricular myocytes by blocking the delayed rectifier potassium current. , 1999, The Journal of pharmacology and experimental therapeutics.

[15]  A. Wilde,et al.  "Brugada" syndrome: clinical data and suggested pathophysiological mechanism. , 1999, Circulation.

[16]  D. Roden,et al.  Drug‐Induced J Point Elevation , 1999, Journal of cardiovascular electrophysiology.

[17]  H. Inoue,et al.  ST Segment Elevation in the Right Precordial Leads Induced with Class IC Antiarrhythmic Drugs , 1999, Journal of cardiovascular electrophysiology.

[18]  J. Towbin,et al.  The Brugada syndrome: clinical, electrophysiologic and genetic aspects. , 1999, Journal of the American College of Cardiology.

[19]  M. Josephson,et al.  ST Segment Elevation Induced by Class IC Antiarrhythmic Agents: Underlying Electrophysiologic Mechanisms and Insights into Drug‐Induced Proarrhythmia , 1998, Journal of cardiovascular electrophysiology.

[20]  T. McIntosh,et al.  The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. , 1998, The Journal of clinical investigation.

[21]  D. Roden.  Taking the “Idio” out of “Idiosyncratic”: Predicting Torsades de Pointes , 1998, Pacing and clinical electrophysiology : PACE.

[22]  J. Brachmann,et al.  Electrocardiographic and Clinical Predictors of Torsades de Pointes Induced by Almokalant Infusion in Patients with Chronic Atrial Fibrillation or Flutter: A Prospective Study , 1998, Pacing and clinical electrophysiology : PACE.

[23]  J. Brachmann,et al.  Electrocardiographic and Clinical Predictors of Torsades de Pointes Induced by Almokalant Infusion in patients With Chronic Atrial Fibrillatio and Flutter , 1998 .

[24]  P. Coumel,et al.  KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome. , 1997, Circulation.

[25]  D M Roden,et al.  Rapid inactivation determines the rectification and [K+]o dependence of the rapid component of the delayed rectifier K+ current in cardiac cells. , 1997, Circulation research.

[26]  U. Meyer,et al.  Molecular mechanisms of genetic polymorphisms of drug metabolism. , 1997, Annual review of pharmacology and toxicology.

[27]  C. January,et al.  Torsade de pointes with an antihistamine metabolite: potassium channel blockade with desmethylastemizole. , 1996, Journal of the American College of Cardiology.

[28]  D. Wysowski,et al.  Cisapride and fatal arrhythmia. , 1996, The New England journal of medicine.

[29]  D. Roden,et al.  Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence. , 1996, Circulation.

[30]  F. Collins,et al.  The geneticist's approach to complex disease. , 1996, Annual review of medicine.

[31]  M. Ingelman-Sundberg,et al.  Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. , 1995, The Journal of pharmacology and experimental therapeutics.

[32]  M. Sanguinetti,et al.  A mechanistic link between an inherited and an acquird cardiac arrthytmia: HERG encodes the IKr potassium channel , 1995, Cell.

[33]  M. Lehmann,et al.  Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs , 1993 .

[34]  L. Carlsson,et al.  Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations. , 1993, Cardiovascular research.

[35]  C. Antzelevitch,et al.  Differences in the Electrophysiological Response of Canine Ventricular Epicardium and Endocardium to Ischemia Role of the Transient Outward Current , 1993, Circulation.

[36]  Y Chen,et al.  Mechanism of the cardiotoxic actions of terfenadine. , 1993, JAMA.

[37]  C. Antzelevitch,et al.  Flecainide‐Induced Arrhythmia in Canine Ventricular Epicardium Phase 2 Reentry? , 1993, Circulation.

[38]  M. Lehmann,et al.  Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. , 1993, JAMA.

[39]  Philippe Amouyel,et al.  Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction , 1992, Nature.

[40]  C. Bahr,et al.  Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype , 1991, Clinical pharmacology and therapeutics.

[41]  D. Snyders,et al.  Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. , 1990, Circulation.

[42]  D. Roden,et al.  Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. , 1986, American heart journal.

[43]  G. Kay,et al.  Torsade de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. , 1983, Journal of the American College of Cardiology.

[44]  G. Cocco,et al.  Torsades de pointes as a manifestation of mexiletine toxicity. , 1980, American heart journal.

[45]  J. Oates,et al.  Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. , 1978, The New England journal of medicine.

[46]  J. Idle,et al.  POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN , 1977, The Lancet.

[47]  J. Cummings,et al.  Quinidine Syncope: Paroxysmal Ventricular Fibrillation Occurring during Treatment of Chronic Atrial Arrhythmias , 1964, Circulation.

[48]  V. McKusick,et al.  Genetic Control of Isoniazid Metabolism in Man , 1960, British medical journal.

[49]  K. F. Wenckebach.  CINCHONA DERIVATIVES IN THE TREATMENT OF HEART DISORDERS , 1923 .